BUPRENORPHINE EXTENDED-RELEASE - SUBCUTANEOUS INJECTION
PHONETIC PRONUNCIATION: (BUE-pre-NOR-feen)
COMMON BRAND NAME(S): Sublocade
GENERIC NAME(S): buprenorphine
Uses
USES: Buprenorphine is used to treat opioid (narcotic) use disorder. This long-acting form of buprenorphine should be used only after treatment with a transmucosal form of buprenorphine (one that is used under the tongue or inside the cheek) has been taken for at least 7 days. Buprenorphine belongs to a class of drugs known as mixed opioid agonist-antagonists. It helps prevent withdrawal symptoms caused by stopping other opioids. It is used as part of a complete treatment program for opioid use disorder (such as compliance monitoring, counseling, behavioral contract, lifestyle changes).
How to use BUPRENORPHINE EXTENDED-RELEASE - SUBCUTANEOUS INJECTION
HOW TO USE: Read the Medication Guide provided by your pharmacist before you start using buprenorphine and each time you get a refill. If you have any questions, ask your doctor or pharmacist. This medication is given by injection under the skin as directed by your doctor, usually once a month. The injection is given in your abdomen by a health care professional. After injection, this medication changes from a liquid to a solid form (depot). You may see or feel a small bump under your skin at the injection site for several weeks. The bump will get smaller over time. Do not try to remove the depot. Do not rub or massage the injection site. Try not to let belts or clothing waistbands rub against the injection site. The dosage is based on your medical condition and response to treatment. For the best effect, use this medication regularly. To help you remember, it may help to mark your calendar. If you miss a dose, contact your doctor or pharmacist right away. If you suddenly stop using this medication, you may have withdrawal symptoms (such as restlessness, watering eyes, runny nose, nausea, sweating, muscle aches). To help prevent withdrawal, your doctor may lower your dose slowly. Withdrawal is more likely if you have used buprenorphine for a long time or in high doses. Tell your doctor or pharmacist right away if you have withdrawal.
Side Effects
Precautions
Interactions
Overdose
Images
Reviews
Faq for BUPRENORPHINE EXTENDED-RELEASE - SUBCUTANEOUS INJECTION
Buprenorphine extended-release subcutaneous injection is used for the treatment of opioid dependence in adults.
Buprenorphine, the active ingredient in this medication, binds to the same receptors in the brain as opioids to reduce cravings and withdrawal symptoms. It helps patients manage their addiction and decrease the risk of relapse.
Buprenorphine extended-release subcutaneous injection is given as a single monthly injection by a healthcare professional. It is typically injected into the abdomen, upper arm, or thigh.
The starting dose of buprenorphine extended-release subcutaneous injection is typically 300 mg, followed by once-monthly maintenance doses of 100 mg. However, individual dosing may vary depending on the patient's response and specific needs.
The most common side effects include injection site reactions (pain, itching, redness), constipation, nausea, headache, and dizziness. It is important to report any adverse reactions to your healthcare provider.
There are limited data on the use of buprenorphine extended-release subcutaneous injection in pregnant women. It is recommended to discuss the risks and benefits with a healthcare professional before initiating or continuing treatment.
Buprenorphine extended-release subcutaneous injection may interact with certain medications, including benzodiazepines and other central nervous system depressants. It is important to inform your healthcare provider about all medications you are taking to avoid potential drug interactions.
Buprenorphine itself is a partial opioid agonist, meaning it has a lower potential for abuse and dependence compared to full opioid agonists. However, like any medication, it should be used as prescribed and under medical supervision to prevent misuse and addiction.
Abrupt discontinuation of buprenorphine extended-release subcutaneous injection can lead to withdrawal symptoms. It is important to work closely with your healthcare provider to safely taper off the medication when discontinuing treatment.
Warning
WARNING: This medication must be given only by injection under the skin. This form of buprenorphine changes from a liquid to a solid form upon contact with body fluids, so giving it by injection into a vein or muscle may cause serious harm or death. Blockage, dangerous blood clots, or local injury can happen if this medication is not used properly. For patients to receive this medication, all doctors, pharmacists, and patients must agree to, understand, and carefully follow the requirements of the Sublocade REMS Program. These requirements apply in the United States. If you live in Canada or any other country, consult your doctor and pharmacist for your country's regulations.
Disclaimer
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
No Reviews Yet